The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

  • STATUS
    Recruiting
  • End date
    Apr 29, 2025
  • participants needed
    300
  • sponsor
    Innovent Biologics (Suzhou) Co. Ltd.
Send
Updated on 19 February 2024
See if I qualify

Summary

This is a phase III randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb in combination with CTLA4 mAb for injection compared to high-Dose interferon in patients with acral melanoma that has been removed by surgery.

Details
Condition Acral Melanoma That Has Been Removed by Surgery
Age 18-75 years
Treatment IBI310+IBI308, IBI308, High-dose recombinant interferon a-2B
Clinical Study IdentifierNCT04277663
SponsorInnovent Biologics (Suzhou) Co. Ltd.
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male and Female aged between 18 and 75 years are eligible
It was confirmed by histopathology that it was a acral melanoma
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Complete excision of primary focal area, surgical incision; All patients must have disease-free status documented by a complete physical examination and imaging studies prior to registration
No adjuvant therapy was received
No treatment contraindication, peripheral blood, normal liver, kidney function and electrocardiogram are normal; ANC1.510^9/L,PLT9010^9/L,Hgb90.g/dL; serum urea nitrogen, cr1.5 _ULN; ALT,ASTI2.5_ ULN
Female subjects of childbearing age or male subjects of women of childbearing age need effective contraception during the entire treatment period and 6 months after the treatment period

Exclusion Criteria

Mucosal-derived melanoma, uveal melanoma
Previous exposure to any anti-CTLA-4, anti-PD-1, anti-PD-L1 / 2 antibody or interferon
Hyperthyroidism or hypothyroidism. Note: Subjects who are stable after hormone replacement therapy can be enrolled
Participate in another clinical study at the same time
Have received any research drug within 4 weeks before the first dose of study treatment
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.